Dr. Helen H. Moon

Claim this profile

Kaiser Permanente-Riverside

Studies Cancer
Studies Bladder Cancer
13 reported clinical trials
23 drugs studied

Area of expertise

1Cancer
Helen H. Moon has run 8 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Bladder Cancer
Helen H. Moon has run 4 trials for Bladder Cancer. Some of their research focus areas include:
Stage III
HER2 positive
Stage IV

Affiliated Hospitals

Image of trial facility.
Kaiser Permanente-Riverside
Image of trial facility.
Kaiser Permanente-Fontana

Clinical Trials Helen H. Moon is currently running

Image of trial facility.

Atezolizumab + Chemotherapy

for Neuroendocrine Carcinoma

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.
Recruiting1 award Phase 2 & 310 criteria
Image of trial facility.

APL-101

for Lung Cancer

Recruiting1 award Phase 211 criteria

More about Helen H. Moon

Clinical Trial Related7 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Helen H. Moon has experience with
  • Nivolumab
  • Ipilimumab
  • Atezolizumab
  • Cisplatin
  • Carboplatin
  • Disitamab Vedotin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Helen H. Moon specialize in?
Helen H. Moon focuses on Cancer and Bladder Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Helen H. Moon currently recruiting for clinical trials?
Yes, Helen H. Moon is currently recruiting for 8 clinical trials in Riverside California. If you're interested in participating, you should apply.
Are there any treatments that Helen H. Moon has studied deeply?
Yes, Helen H. Moon has studied treatments such as Nivolumab, Ipilimumab, Atezolizumab.
What is the best way to schedule an appointment with Helen H. Moon?
Apply for one of the trials that Helen H. Moon is conducting.
What is the office address of Helen H. Moon?
The office of Helen H. Moon is located at: Kaiser Permanente-Riverside, Riverside, California 92505 United States. This is the address for their practice at the Kaiser Permanente-Riverside.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.